Metastatic or recurrent endometrial cancer.

This review will end up being an important event in our advancement of zoptarelin doxorubicin. We are looking towards learning the outcomes of the DSMB's analysis.’ Commenting on the compound, Dr. Richard Sachse, the Company's Chief Medical and Chief Scientific Officer, stated, ‘We think that zoptarelin doxorubicin has the potential to be the first FDA approved medical therapy for advanced, recurrent endometrial tumor. This could result in its fast adoption as a novel primary therapy for administration and treatment of advanced, recurrent endometrial cancers. Our wish is that the compound will improve and lengthen the quality of the lives of patients with this devastating disease.’..The EHR is normally touted as a cost-saving, quality-promoting tool, though cost-saving projections have already been debunked and data on quality are blended.2 Although we’ve made improvement in patient safety only by carefully examining our errors, the hazards posed by technology are expected to right themselves somehow. Second, letting the market form usability assumes that clinicians are the target users. Therefore EHRs will be just as good as the product quality metrics they’re made to capture; technology can’t conquer fundamental measurement issues. We measure many things that have no value to patients, while much of what patients do worth, including our attention, remains unmeasurable. Why, Wachter asks, perform we do nothing identical in health care? In a moving passage, Wachter speaks with a famous surgeon who once spent his evenings before surgery reading his notes on another day’s patients.